Regenics’ have recieved a series of public grants supporting development of Vernex® wound healing hydrogel from a.o. Eurostars, BIA, PES2020, Innovation Norway and SkatteFUNN.

The total granted amounts to approx. 21 mill NOK with present funding programs (below) active until 2018.

Present ongoing support programs:

BIA: Proj. no.: 245553 Bioactive salmon roe substances in wound healing.

Eurostars: Proj. no.:   247714 E!9477 Development of wound healing device with salmon roe wound healing ingredient

In the period 2015 - 2017 the cash funded from the above sources equal to 15 mill NOK, total project cost thus is approx. 30 mill NOK. 

 

The prospective profile of Vernex® will support scientifically documented and patented claims:

  • VERNEX® speeds up reepitelialization of wounds
  • VERNEX® skin safety tested
  • VERNEX® causes no irritation or sensitization
  • VERNEX® delivered as hydrogel formulation
  • VERNEX® increases fibroblast migration
  • VERNEX® increases collagen synthesis
  • VERNEX® enhances hyaluronic acid secretion
  • VERNEX® increases elastin production

Regenics AS has developed a number of assays and techniques to study effects of various substances on skin cells both in vitroin vivo and in the clinic. Our focus is to develop products and techniques for therapeutic skin applications and to improve skin appearance.